Sugi Predict

Sugi Predict / Compounds / SCHEMBL1816625

SCHEMBL1816625

SCHEMBL1816625

CCOC(=O)c1cc(-c2cccnc2)n[nH]1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALPL P05186 3/20 0.64
▸ MAPT P10636 5/20 0.63
▸ RAB9A P51151 4/20 0.63
▸ NPC1 O15118 3/20 0.63
▸ L3MBTL1 Q9Y468 1/20 0.63
▸ MMP2 P08253 1/20 0.62
▸ MMP13 P45452 1/20 0.62
▸ MMP14 P50281 1/20 0.62
▸ HPGDS O60760 2/20 0.61
▸ ALK Q9UM73 1/20 0.57
▸ KMT2A Q03164 1/20 0.56
▸ TP53 P04637 1/20 0.54
▸ CASP3 P42574 1/20 0.54
▸ SENP8 Q96LD8 1/20 0.54
▸ SENP7 Q9BQF6 1/20 0.54
▸ SENP6 Q9GZR1 1/20 0.54
▸ GAA P10253 1/20 0.53
▸ HDAC3 O15379 1/20 0.53
▸ HDAC4 P56524 1/20 0.53
▸ HDAC1 Q13547 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL595997 0.86 ALPL (0.75) ALPLMAPTRAB9ANPC1L3MBTL1
SCHEMBL4712555 0.85 ALPL (0.73) ALPLMAPTRAB9ANPC1L3MBTL1
SCHEMBL4428979 0.84 ALK (0.53) ALPLMAPTRAB9ANPC1L3MBTL1
SCHEMBL23755314 0.83 MAPT (0.70) ALPLMAPTRAB9ANPC1L3MBTL1
SCHEMBL31412612 0.83 ALPL (0.66) ALPLMAPTRAB9ANPC1L3MBTL1
SCHEMBL13710322 0.82 MAPT (0.69) ALPLMAPTRAB9ANPC1L3MBTL1
SCHEMBL16730821 0.82 MAPT (0.69) ALPLMAPTRAB9ANPC1L3MBTL1
SCHEMBL2838868 0.81 HPGDS (0.73) ALPLMAPTRAB9ANPC1L3MBTL1
SCHEMBL2839464 0.81 HPGDS (0.70) ALPLMAPTRAB9ANPC1L3MBTL1
SCHEMBL16699171 0.81 ALPL (0.74) ALPLMAPTRAB9ANPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570675-B2 Boronic acid compounds LG CHEM, LTD. (KR) 2026-03-10 — — US disclosed
EP-3885340-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2024-11-27 — — EP disclosed
US-20240101579-A1 BORONIC ACID COMPOUNDS LG CHEM, LTD. (KR) 2024-03-28 — — US disclosed
EP-4242213-A1 BORONIC ACID COMPOUND Lg Chem, Ltd. (KR) 2023-09-13 — — EP disclosed
CN-116568310-A Boric acid compounds 株式会社LG化学 2023-08-08 — — CN disclosed
WO-2022123530-A1 BORONIC ACID COMPOUND 주식회사 엘지화학 2022-06-16 — — WO disclosed
EP-3885340-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2021-09-29 — — EP disclosed
US-11046713-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2021-06-29 — — US disclosed
EP-3369732-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2021-05-26 — — EP disclosed
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2020-09-24 — — US disclosed
US-8921401-B2 Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2014-12-30 — — US disclosed
US-20140274950-A1 PYRAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS MEDICAL UNIVERSITY OF SOUTH CAROLINA (US) 2014-09-18 — — US disclosed
US-20140274950-A1 PYRAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS MEDICAL UNIVERSITY OF SOUTH CAROLINA (US) 2014-09-18 — — US disclosed
EP-2493858-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2014-07-02 — — EP disclosed
US-20120225867-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-09-06 — — US disclosed
EP-2493858-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS Orion Corporation (FI) 2012-09-05 — — EP disclosed
WO-2011051540-A9 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-06-21 — — WO disclosed
WO-2011051540-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2011-05-05 — — WO disclosed
US-6506747-B1 Method of treating an inflammatory disease which comprises administering to a patient in need of such treatment-a N-(4-(5-Ethyl-3-pyridin-3-yl-pyrazol-1-yl)phenyl)pyridine-3-carboxamide; BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-01-14 — — US disclosed
WO-1999062885-A1 SUBSTITUTED 1-(4-AMINOPHENYL)PYRAZOLES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1999-12-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570675-B2 Boronic acid compounds PSMB6, PSMB3, PSMB2 ALPL 3539/4885MAPT 3120/4885RAB9A 715/4885
US-20240101579-A1 BORONIC ACID COMPOUNDS PSMB11, PSMB1, BACH1 ALPL 3964/4885MAPT 685/4885RAB9A 931/4885
US-20140274950-A1 PYRAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS PPARG, PPARD, PC ALPL 412/4885MAPT 391/4885RAB9A 1911/4885
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG ALPL 3230/4885MAPT 3306/4885RAB9A 2470/4885
US-11046713-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG ALPL 3230/4885MAPT 3306/4885RAB9A 2470/4885
US-20120225867-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG ALPL 3230/4885MAPT 3306/4885RAB9A 2470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.